4//SEC Filing
Broennimann Benedict 4
Accession 0001493152-18-016878
CIK 0001661053other
Filed
Nov 28, 7:00 PM ET
Accepted
Nov 29, 5:31 PM ET
Size
5.8 KB
Accession
0001493152-18-016878
Insider Transaction Report
Form 4
Broennimann Benedict
Chief Medical Officer, OUS
Transactions
- Award
Restricted Common Stock
2018-11-27+3,334→ 437,778 total(indirect: By Rosewall Ventures Ltd.)
Footnotes (3)
- [F1]The issuer entered into a services agreement with Rosewall Ventures Ltd. ("Rosewall"), dated May 1, 2018 (the "Service Agreement"), whereby Rosewall is providing the services of Ben Broennimann as the Company's Chief Medical Officer - Out of U.S.. The Service Agreement provides for the monthly payment of fifteen thousand dollars ($15,000) (the " Rosewall Monthly Fee"), provided however that the Company may, at its sole option, elect to pay twenty five percent (25%) of the Rosewall Monthly Fee in company common stock, par value $0.0001 per share (the "Common Stock"), with the number of Common Stock determined by dividing three thousand seven hundred fifty dollars ($3,750) by the closing price of Common Stock on the second (2nd) work day of each month. On November 27, 2018, the Company elected to issue Rosewall Common Stock for the months of October and November.
- [F2]The closing price of the Common Stock on the 2nd work day of October was $2.57 and it was $2.00 for the 2nd work day of November.
- [F3]Dr. Benedict Broennimann is the chairman of Rosewall Ventures Ltd.
Documents
Issuer
Hancock Jaffe Laboratories, Inc.
CIK 0001661053
Entity typeother
Related Parties
1- filerCIK 0001730165
Filing Metadata
- Form type
- 4
- Filed
- Nov 28, 7:00 PM ET
- Accepted
- Nov 29, 5:31 PM ET
- Size
- 5.8 KB